Neurophth Therapeutics
China - WuhanBiotechnology
Focus: Neurophth Therapeutics is a gene therapy biotech focused on ophthalmology, specifically developing treatments for Leber Hereditary Optic Neuropathy (LHON). Founded in 2021 and headquartered in Wuhan, China, the company operates as a pre-revenue biotech with a targeted pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Neurophth Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Neurophth Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
NR082 Injection
Leber Hereditary Optic Neuropathy (LHON)Clinical Trials (1)
NCT05293626Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations
Phase 1/2Help build intelligence for Neurophth Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.